Skip to main content

Immunome Inc.

IMNM
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001472012

In the last 90 days, Immunome Inc. insiders filed 0 open-market purchases and 9 sales; 202 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Immunome Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
9 filings
4 insiders, $14.9M in total
Insiders trading
4
Net value
−$14.9M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Immunome Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Immunome Inc.
NameTitleLast reported holdingLast filingFilings, past year
Higgins JackChief Scientific Officer56,250Sep 15, 20265
Barchas IsaacDirector92,211Aug 12, 20266
Horn KinneyCHIEF BUSINESS OFFICER0Aug 6, 20263
Tsai PhilipChief Technical Officer81,550Jul 27, 20262
Stoneman Sandra G.CHIEF LEGAL OFFICER & GC43,805Jul 27, 20261
Rosett MaxChief Financial Officer101,287Jul 27, 20263
Lechleider RobertChief Medical Officer69,805Jul 27, 20263
Siegall Clay BPresident and CEO870,704Jul 27, 20265
Bienaime Jean JacquesDirector43,415Jun 12, 20264
Schafer CarolDirector–Jun 12, 20261
Wagenheim PhilipDirector341,147Jun 12, 20262
Swain Sandra MDirector–Jun 12, 20261
Boylan James PDirector–Jun 12, 20261
Turner BruceChief Strategy Officer42,300Aug 13, 20240
Roberts Phil NolandChief Technology Officer–Dec 15, 20230
Prendergast Franklyn GDirector60,840Oct 4, 20230
Rapp MichaelDirector1,071,172Oct 3, 20230
Lamattina John LDirector66,953Jun 12, 20230
Baron Richard ADirector2,343Jun 12, 20230
Sarma Purnanand DPresident and CEO–Jun 12, 20230
Lefenfeld MichaelDirector40,747Jun 12, 20230
Giesing Dennis HChief Development Officer–Jun 12, 20230
Roche Corleen M.Chief Financial Officer–Jun 12, 20230
Robinson Matthew KChief Technology Officer–Jun 12, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 15, 2026 (view filing)4:30 PM ETSep 114 daysHiggins JackChief Scientific OfficerSSale−13.2K$25.32−$334.2K−16.9%65.0K after10b5-1
Aug 12, 2026 (view filing)5:47 PM ETAug 10-112 daysBarchas IsaacDirectorSSale−72.4K$26.21−$1.90M−100.0%0 after2 lots10b5-1
Aug 12, 2026 (view filing)5:47 PM ETAug 12Same dayBarchas IsaacDirectorSSale−11.0K$27.25−$301.1K−10.7%92.2K after10b5-1
Aug 10, 2026 (view filing)4:10 PM ETAug 6-74 daysBarchas IsaacDirectorSSale−36.1K$26.06−$940.5K−33.3%72.4K after2 lots10b5-1
Aug 6, 2026 (view filing)6:30 PM ETAug 42 daysHorn KinneyCHIEF BUSINESS OFFICERSSale−90.6K$25.09−$2.27M−100.0%0 after10b5-1
Jul 9, 2026 (view filing)5:38 PM ETJul 72 daysHorn KinneyCHIEF BUSINESS OFFICERSSale−1.09K$25.00−$27.3K−100.0%0 after10b5-1
Jul 7, 2026 (view filing)7:02 PM ETJul 6-71 dayBarchas IsaacDirectorSSale−100.0K$24.13−$2.41M−48.0%108.5K after2 lots10b5-1
Jul 7, 2026 (view filing)5:42 PM ETJul 25 daysLechleider RobertChief Medical OfficerSSale−55.0K$22.62−$1.24M−77.7%15.8K after3 lots10b5-1
Jul 2, 2026 (view filing)8:31 PM ETJun 30-Jul 22 daysBarchas IsaacDirectorSSale−201.1K$21.85−$4.39M−49.1%208.5K after3 lots10b5-1
Jun 29, 2026 (view filing)Jun 254 daysLechleider RobertChief Medical OfficerSSale−55.0K$19.85−$1.09M−77.7%15.8K after2 lots10b5-1
Jun 17, 2026 (view filing)Jun 152 daysRosett MaxChief Financial OfficerSSale−60.0K$18.23−$1.09M−52.6%54.0K after10b5-1
Jun 9, 2026 (view filing)Jun 54 daysBienaime Jean JacquesDirectorSSale−10.5K$19.41−$203.8K−24.2%32.9K after2 lots
Jun 9, 2026 (view filing)Jun 54 daysBienaime Jean JacquesDirectorPPurchase+10.5K$19.45+$204.3K+31.9%43.4K after3 lots
May 19, 2026 (view filing)May 154 daysBienaime Jean JacquesDirectorPPurchase+5.00K$20.70+$103.5K+13.0%43.4K after
Apr 3, 2026 (view filing)Apr 21 dayRosett MaxChief Financial OfficerSSale−65.0K$21.92−$1.42M−54.6%54.0K after2 lots10b5-1
Apr 3, 2026 (view filing)Apr 21 dayHiggins JackChief Scientific OfficerSSale−9.44K$21.64−$204.2K−30.0%22.0K after10b5-1
Mar 31, 2026 (view filing)Mar 274 daysSiegall Clay BPresident and CEOPPurchase+25.4K$19.67+$500.6K+3.8%690.7K after
Mar 23, 2026 (view filing)Mar 20-233 daysWagenheim PhilipDirectorSSale−65.0K$20.55−$1.34M−16.0%341.1K after2 lots
Mar 12, 2026 (view filing)Mar 10-112 daysBienaime Jean JacquesDirectorPPurchase+2.00K$21.84+$43.7K+5.5%38.4K after2 lots
Dec 30, 2025 (view filing)Dec 30Same daySiegall Clay BPresident and CEOPPurchase+4.73K$21.15+$100.0K+0.7%665.3K after
Dec 23, 2025 (view filing)Dec 221 dayBarchas IsaacDirectorSSale−383.2K$21.74−$8.33M−15.9%2.03M after2 lots10b5-1
Dec 22, 2025 (view filing)Dec 193 daysTsai PhilipChief Technical OfficerPPurchase+10.0K$20.49+$204.9K+30.0%43.3K after
Dec 22, 2025 (view filing)Dec 193 daysSiegall Clay BPresident and CEOPPurchase+7.28K$20.48+$149.1K+0.9%860.5K after
Dec 18, 2025 (view filing)Dec 18Same daySiegall Clay BPresident and CEOPPurchase+46.5K$21.50+$1.00M+5.8%853.2K after
Jun 3, 2025 (view filing)Jun 3Same dayBienaime Jean JacquesDirectorPPurchase+5.00K$9.38+$46.9K+15.9%36.4K after
Mar 26, 2025 (view filing)Mar 251 dayBienaime Jean JacquesDirectorPPurchase+7.80K$7.78+$60.7K+33.0%31.4K after
Mar 26, 2025 (view filing)Mar 26Same daySiegall Clay BPresident and CEOPPurchase+137.1K$7.29+$999.5K+20.5%806.7K after
Mar 25, 2025 (view filing)Mar 241 dayBienaime Jean JacquesDirectorPPurchase+7.00K$8.21+$57.5K+42.1%23.6K after
Mar 25, 2025 (view filing)Mar 241 dayTsai PhilipChief Technology OfficerPPurchase+12.3K$8.42+$103.6K+58.6%33.3K after
Feb 3, 2025 (view filing)Jan 313 daysSiegall Clay BPresident and CEOPPurchase+150.0K$7.75+$1.16M+28.9%669.6K after
Nov 25, 2024 (view filing)Nov 21-224 daysSiegall Clay BPresident and CEOPPurchase+100.0K$9.62+$962.1K+23.8%519.6K after2 lots
Nov 25, 2024 (view filing)Nov 214 daysLechleider RobertChief Medical OfficerPPurchase+15.8K$9.48+$149.8KNew position15.8K after
Nov 25, 2024 (view filing)Nov 214 daysTsai PhilipChief Technology OfficerPPurchase+21.0K$9.43+$198.0KNew position21.0K after
Sep 20, 2024 (view filing)Sep 191 dayRosett MaxChief Financial OfficerSSale−14.4K$16.01−$230.2K−23.2%47.5K after
Aug 19, 2024 (view filing)Aug 163 daysBienaime Jean JacquesDirectorPPurchase+7.00K$13.94+$97.6K+72.8%16.6K after
Aug 19, 2024 (view filing)Aug 154 daysHiggins JackChief Scientific OfficerSSale−3.52K$13.93−$49.1K−18.0%16.0K after
May 22, 2024 (view filing)May 211 dayBienaime Jean JacquesDirectorPPurchase+2.00K$13.57+$27.1K+26.3%9.62K after
May 21, 2024 (view filing)May 20-211 daySiegall Clay BPresident and CEOPPurchase+100.0K$13.88+$1.39M+31.3%419.6K after2 lots
Oct 4, 2023 (view filing)Oct 22 daysSiegall Clay BPresident and CEOPPurchase+169.2K$5.91+$1.00M+112.5%319.6K after
Oct 4, 2023 (view filing)Oct 22 daysTurner BruceChief Strategy OfficerPPurchase+42.3K$5.91+$250.0KNew position42.3K after
Sep 14, 2021 (view filing)Sep 131 dayRapp MichaelDirectorPPurchase+26.0K$19.96+$518.2K+14.2%208.7K after
Sep 13, 2021 (view filing)Sep 9-104 daysRapp MichaelDirectorPPurchase+46.0K$18.07+$830.4K+33.6%182.8K after3 lots